Key Laboratory of Medical Immunology, Ministry of Health, Peking University Health Science Center, Beijing, China.
Cancer Lett. 2013 Jan 1;328(1):126-34. doi: 10.1016/j.canlet.2012.08.032. Epub 2012 Sep 4.
TMEM166 is a novel programmed cell death-related molecule. In this report, we constructed a recombinant adenovirus 5-TMEM166 vector (Ad5-TMEM166) and evaluated its expression and anti-tumor activities in vitro and in vivo. Cell viability analysis revealed that the adenovirus-mediated increase of TMEM166 inhibited tumor cell growth in a dose- and time-dependent manner. This inhibitory effect was mediated by both autophagy (via inhibition of mTOR and activation of p70S6K) and apoptosis (via caspase-3 activation), both of which contributed to cell death and suppression of tumorigenicity. Our data indicated that Ad5-TMEM166 may be a novel gene therapy candidate for cancer.
TMEM166 是一种新型的程序性细胞死亡相关分子。在本报告中，我们构建了重组腺病毒 5-TMEM166 载体（Ad5-TMEM166），并在体外和体内评估了其表达和抗肿瘤活性。细胞活力分析表明，腺病毒介导的 TMEM166 增加以剂量和时间依赖的方式抑制肿瘤细胞生长。这种抑制作用是通过自噬（通过抑制 mTOR 和激活 p70S6K）和细胞凋亡（通过 caspase-3 激活）介导的，这两者都导致细胞死亡和抑制肿瘤发生。我们的数据表明，Ad5-TMEM166 可能是癌症的一种新型基因治疗候选物。
